Documentos relacionados

1. Assessment of quantitative polymerase chain reaction for BCR-ABL1 transcripts in chronic myeloid leukaemia: Are improved outcomes in patients with e14a2 transcripts an artefact of technology?
2. Chronic myeloid leukemia (CML) in children and adolescents-Clinicopathological findings.
3. Feasibility of treatment-free remission with generic imatinib: Results of generic imatinib-free trial-in-chronic myeloid leukaemia-chronic phase study.
4. Aplastic anemia secondary to tyrosine kinase inhibitor therapy in a patient with chronic myeloid leukemia.
5. Tyrosine Kinase Inhibitor Therapies in Chronic Myeloid Leukemia: Effects on Clinical Characteristics and Triglyceride-to-High Density Lipoprotein Cholesterol Ratio.
6. Clinical outcomes of second-generation tyrosine kinase inhibitors versus imatinib in older patients with CML.
7. <i>MDR1</i> gene polymorphisms and imatinib response in chronic myeloid leukemia: A meta-analysis.
8. A single-cell atlas identifies pretreatment features of primary imatinib resistance in chronic myeloid leukemia.
9. Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study.
10. Late relapse of chronic myeloid leukemia after allogeneic bone marrow transplantation points to KANSARL (KANSL1::ARL17A) alteration: a case report with insights on the molecular landscape.